News & Blog

News & Blog

  • Reset
News | Dec 15 2023

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Industry News
Blog | Dec 11 2023

Meet the Community – Fabian B

Community
Blog | Dec 4 2023

Meet the Community – Marguerite Black

Community
Blog | Nov 20 2023

Meet the Community – Katie Snead

Community
Blog | Nov 13 2023

Meet the Community 2: A Closer Look – Don Royer

Community
Blog | Nov 1 2023

Meet the Community – Silvia

Community
Blog | Oct 16 2023

Meet the Community 2: A Closer Look – Jakob Mitterhauser

Community
News | Sep 26 2023

Biogen Completes Acquisition of Reata Pharmaceuticals

Industry News
Blog | Sep 18 2023

Meet the Community 2: A Closer Look – Tiffany Rose Gambill

Community
Blog | Sep 14 2023

Meet the Community – Sam Bridgman

Community
Blog | Sep 5 2023

Meet the Community – Lilly Woods

Community
News | Aug 14 2023

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels i...

Industry News